Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CD200 Activation Receptor Ligand - OX2 Therapeutics; CD200AR-L; hP1A8

Latest Information Update: 27 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Minnesota
  • Developer OX2 Therapeutics
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioblastoma; Glioma
  • Preclinical Lung cancer; Malignant melanoma; Solid tumours

Most Recent Events

  • 27 Mar 2024 Phase I development for Glioblastoma is ongoing in the US
  • 15 Mar 2024 Phase-I clinical trials in Glioma (Recurrent, Second-line therapy or greater, Combination therapy) in USA (unspecified route) (NCT06305910)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent, Second-line therapy or greater) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top